Literature DB >> 10353442

Pulmonary epithelial expression of human alpha1-antitrypsin in transgenic mice results in delivery of alpha1-antitrypsin protein to the interstitium.

R Dhami1, K Zay, B Gilks, S Porter, J L Wright, A Churg.   

Abstract

Alpha1-antitrypsin (alpha1AT) therapy is used as a treatment for alpha1AT deficiency. It has also been proposed as a therapy for cigarette smoke-induced emphysema, although the efficacy of such therapy is as yet unproven. Moreover, the optimal route of delivery of alpha1AT to the lung interstitium, the crucial locus of action, is unknown. We created transgenic mice with expression of the human alpha1AT gene directed by a human surfactant protein C (SpC) promoter fragment or a rat Clara cell 10-kDa protein (CC10) promoter fragment in order to examine the ability of pulmonary epithelial cell expression of alpha1AT to deliver protein to the interstitium, and to produce a model that would allow studies on the efficacy of alpha1AT in preventing lung damage after cigarette smoke exposure. Four transgenic lines were studied. In situ hybridization and light microscopic immunohistochemistry showed that two CC10 driven lines expressed human alpha1AT in type 11 alveolar cells and airway epithelial cells; alpha1AT expression was seen in the alveolar parenchyma in two SpC driven lines, and in small airway epithelium in one of the SpC lines. Electron microscopic immunochemistry showed the presence of the human alpha1AT protein in the interstitium in all lines. Mean levels of human protein varied from 0.37 to 2.9 microg/g lung protein and serum levels from 0.72 to 1.3 microg/ml, compared to normal human serum alpha1AT levels of 2-5 mg/ml. We conclude that transgene-mediated expression of alpha1AT in pulmonary epithelial cells results in diffuse expression of the transgene in the alveolar parenchyma and reproducibly leads to transfer of protein to the interstitium. The present model is, however, limited by low levels of protein production; limited protein production may be a problem in other forms of gene therapy in which relatively large amounts of extracellular protein are needed in the lung for a therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353442     DOI: 10.1007/s001090050364

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  15 in total

1.  α-1-antitrypsin gene delivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection.

Authors:  Galit Shahaf; Hadas Moser; Eyal Ozeri; Mark Mizrahi; Avishag Abecassis; Eli C Lewis
Journal:  Mol Med       Date:  2011-06-09       Impact factor: 6.354

2.  Human α1-antitrypsin modifies B-lymphocyte responses during allograft transplantation.

Authors:  Mark Mizrahi; Pablo Cal; Martin Rosenthal; David Ochayon; Galit Shahaf; Ziv Kaner; Peter Kachker; Eli C Lewis
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

3.  Enhanced Survival and Accelerated Perfusion of Skin Flap to Recipient Site Following Administration of Human α1-Antitrypsin in Murine Models.

Authors:  Ronen Schuster; Or Bar-Nathan; Alon Tiosano; Eli C Lewis; Eldad Silberstein
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-07-02       Impact factor: 4.730

Review 4.  Expanding the clinical indications for α(1)-antitrypsin therapy.

Authors:  Eli C Lewis
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

5.  Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice.

Authors:  Sandhya Subramanian; Galit Shahaf; Eyal Ozeri; Lisa M Miller; Arthur A Vandenbark; Eli C Lewis; Halina Offner
Journal:  Metab Brain Dis       Date:  2011-03-25       Impact factor: 3.584

6.  Oncostatin M induced alpha1-antitrypsin (AAT) gene expression in Hep G2 cells is mediated by a 3' enhancer.

Authors:  Kevin Morgan; Peter Marsters; Stephen Morley; Diana van Gent; Ala Hejazi; Matt Backx; Emma R K Thorpe; Noor Kalsheker
Journal:  Biochem J       Date:  2002-07-15       Impact factor: 3.857

7.  alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice.

Authors:  Eli C Lewis; Mark Mizrahi; Michel Toledano; Nathaniel Defelice; Joanne L Wright; Andrew Churg; Leland Shapiro; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

8.  Tobacco smoke induced COPD/emphysema in the animal model-are we all on the same page?

Authors:  Maike Leberl; Adelheid Kratzer; Laimute Taraseviciene-Stewart
Journal:  Front Physiol       Date:  2013-05-15       Impact factor: 4.566

9.  Overexpression of sICAM-1 in the alveolar epithelial space results in an exaggerated inflammatory response and early death in Gram negative pneumonia.

Authors:  Michael P Mendez; Yeni K Monroy; Ming Du; Angela M Preston; Leslie Tolle; Yujing Lin; Kelli L VanDussen; Linda C Samuelson; Theodore J Standiford; Jeffery L Curtis; James M Beck; Paul J Christensen; Robert Paine
Journal:  Respir Res       Date:  2011-01-19

10.  Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapy.

Authors:  Efrat Ashkenazi; Boris M Baranovski; Galit Shahaf; Eli C Lewis
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.